

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/58, 31/57, 31/565</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/49407</b> <b>(43) International Publication Date:</b> 31 December 1997 (31.12.97)
<b>(21) International Application Number:</b> PCT/EP97/03288 <b>(22) International Filing Date:</b> 23 June 1997 (23.06.97) <b>(30) Priority Data:</b> 96201744.8 25 June 1996 (25.06.96) EP <b>(34) Countries for which the regional or international application was filed:</b> AT et al. <b>(71) Applicant (for all designated States except US):</b> AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> COELINGH BENNINK, Herman, Jan, Tijmen [NL/NL]; Melvill van Carnebeeklaan 38, NL-3971 BE Driebergen (NL). VERBOST, Pieter, M. [NL/NL]; Plantsoen 15, NL-5384 ET Heesch (NL). <b>(74) Agent:</b> KRAAK, Hajo; P.O. Box 20, NL-5340 BH Oss (NL).		<b>(81) Designated States:</b> AU, BR, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RU, SG, TR, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> PROGESTOGEN-ANTI-PROGESTOGEN REGIMENS  <b>(57) Abstract</b>  Disclosed is a contraceptive and/or HRT (hormone replacement therapy) kit comprising sequential daily dosage units each containing as the sole contraceptively effective ingredient of a progestogen, or as effective ingredient for HRT a progestogen with or without an estrogen or an estrogen only, and further two or more dosage units comprising an anti-progestogen. One of the anti-progestogen is administered at the beginning and the others regularly divided throughout the cycle, preferably one only in the middle of the cycle.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## PROGESTOGEN-ANTI-PROGESTOGEN REGIMENS

- 5 The invention relates generally to progestogen-anti-progestogen regimens for use in contraception and hormone replacement therapy, and more specifically for contraception to progestogen-anti-progestogen regimens involving only the administration of a progestogen and an anti-progestogen.
- 10 It has been known for some time that contraception can be achieved by the oral administration of sufficient quantities of a progestogen to a female of child-bearing age. Contraceptive preparations that minimize the incidence of menstrual spotting, break through bleeding, variations in menstrual cycle length and amenorrhea are preferred. It is further preferred to use contraceptive regimens that minimize the
- 15 amounts of estrogens and progestogens used. Preparations that fulfil many of these requirements are disclosed in WO 93/21927, wherein a contraceptive regimen free from estrogens is described, the active ingredient being a progestational agent and intermittently an anti-progestogen. The regimen used is a regimen wherein only levonorgestel is administered as the progestogen, except that on days 1, 30, 60, 90,
- 20 120, 150, and 180 a dosage of the anti-progestogen RU 486 is administered. In fact the regimen is a progestogen-only regimen, interrupted by anti-progestogen administration at the beginning of each cycle. Although this regimen is a considerable improvement over existing regimens comprising estrogens, the bleeding profile is still not perfect since it recurs slowly after an almost bleeding-free interval, and further
- 25 improvement is therefor desirable.

"Progestogen-only pills" are a preferred method of contraception for breast-feeding mothers, older women, women for whom estrogen is contraindicated, women who are hypertensive, and women who develop migraine headaches when taking a combined

30 pill (i.e. one containing an estrogen and progestogen component). See, e.g. "Contraception for women over the age of 35", IPPF Medical Bulletin, 22: 3-4 (1988) and P.W. Howie "The progestogen-only pill", Brit. J. Obstet. Gynaecol., 92: 1001-2 (1985).

While different progestogen-only regimens have been described, they are still associated with incomplete ovulation inhibition, and relatively high failure rates. Vessey et al "Progestogen-only oral contraception. Findings in a large prospective study with special reference to effectiveness", Brit. J. Family Planning, 292: 526-30 (1986). It has been suggested to increase the daily dosage of progestogen in order to induce complete ovulation inhibition, however such an increase in dosage also increases the frequency of intermenstrual bleeding (i.e. "spotting"), which is clearly not desired. E. Diczfalussy et al, Progestogens in Therapy, p. 150 (Raven Press, NY 1983). Moreover, a high prevalence of functional ovarian cysts have been reported with progestogen only contraceptive regimens, which resolve after discontinuation of the progestogen-only contraceptive. Fotherby, K. "The Progestogen-pill", in: Filshie et al eds. Contraception: Science and Practice, pp. 94-108 (1989), and Howie, supra. A need exists for a progestogen-only contraceptive regimen which more effectively inhibits ovulation, while still not increasing the frequency of intermenstrual bleeding, or leading to persistent functional ovarian cysts. The solution to this need by adding intermittently an anti-progestogen needs further elaboration.

Surprisingly it has now been found that apart from administering an anti-progestagen at the beginning of a cycle, by selecting one or more additional days during the cycle, preferably one day in the middle of the cycle, on which the anti-progestogen is administered, whereas over the rest of an entire menstrual cycle (e.g. 28 days) desogestrel or 3-ketodesogestrel is administered as the progestogen at certain specified dosages, complete ovulation inhibition is achieved, while retaining good cycle control and almost completely decreasing the amount of spotting.

The invention thus includes a drug delivery system for contraceptive use containing daily oral dosage units, each unit containing a progestogen, and two or more units comprising an anti-progestogen, one of which is administered at the end and the others orderly divided through the cycle (if one: in the middle of the cycle).

The invention also includes a drug delivery system for HRT (hormone replacement therapy) containing daily oral dosage units, each unit comprising a progestogen with or without an estrogen or an estrogen only, and two or more dosage units comprising an anti-progestogen, one of which is preferably administered at the beginning and the others orderly divided through the cycle.

In general terms the invention relates to a contraceptive and/or HRT (hormone replacement therapy) kit comprising sequential daily dosage units for oral administration each comprising as the sole contraceptively effective ingredient a progestogen, or as effective ingredient for HRT a progestogen with or without an estrogen or an estrogen alone, and further two or more units comprising an anti-progestogen.

If desired the kits may contain placebo pills to bridge two periods of administration of active ingredients. This is usual for contraceptive regimens containing less than 28 dosage units, in order to obtain a kit still having 28 pills (the usual cycle).

The invention also includes a pharmaceutical product (i.e. the dosage units or the package containing the dosage units), a method of using the product, and a process of manufacturing the pharmaceutical product.

The invention also includes a method of providing contraception and/or HRT for a pre-, peri-, or post-menopausal woman involving administering to the woman the above-mentioned regimens.

Progestogens for use with the invention are 3-keto-desogestrel (etonogestrel), desogestrel, gestodene, levonorgestrel, norgestrel and other progestogens commonly used for contraception and HRT. Desogestrel has the chemical name 13-ethyl-11-methylene-18,19-di-nor-17 $\alpha$ -pregn-4-en-20-yn-17-ol, and is the preferred progestogen. Desogestrel is believed to be metabolized in the body into 3-ketodesogestrel. Preferred the dosage units contain 75  $\mu$ g of desogestrel or 3-ketodesogestrel, or amount of other progestogens having the equivalent effect as 75  $\mu$ g of desogestrel. Based on practically applied doses, levonorgestrel, desogestrel, and 3-keto-desogestrel are relatively equipotent in progestogenic activity. Gestodene is approximately 1.5 times as potent as these compounds. Norgestrel is about one-half as potent as levonorgestrel.

30

The anti-progestogen can be an inhibitor of progesterone synthesis, such as epostane, azastene or trilostane (Creange, Contraception 24, 289, 1981; Drugs of the Future 7,

661, 1982, van der Spuy et al., Contraception 35, 111, 1987; US patent 3296255) or a progesterone receptor antagonist, or any such pharmaceutically suitable agent that counteracts the normal biological activity of progesterone, such as antibodies or ligands bindable to progestogens or to the progesterone receptor.

- 5 A suitable anti-progestogen is a progesterone receptor antagonist. For example RU486, Onapristone, Org 31710 [(6 $\alpha$ ,11 $\beta$ ,17 $\beta$ )-11-(4-dimethylaminophenyl)-6-methyl-4',5'-dihydrospiro[estra-4.9-diene-17,2'-(3'H)-furan]-3-one], and Org 33628 [11 $\beta$ ,17 $\alpha$ )-11-(4-acetylphenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one] are particularly suitable in the practice of the present invention.
- 10 Suitable amounts of anti-progestogen are for example 0.1 to 300 mg, and preferably 0.5 to 150 mg of Org 31710 or such amounts of other anti-progestogens which have equivalent activity. The anti-progestogen is administered at the beginning of the cycle, preferably on day 1, and in the middle of the cycle, preferably day 14. More generally, the first of the anti-progestogen dosage units may be administered between days 1 and
- 15 3 (the beginning of the cycle), and the second between days 12 and 16 (the middle of the cycle). In the case of more than one additional day of anti-progestagen administration, these additional days may be, e.g., in the middle of the remaining phases, i.e. anti-progestagen then is administered once a week. Maximally, the anti-progestagen can be administered every 4 days, i.e. for a cyclus of 28 days the number
- 20 of dosage units comprising anti-progestagen is two to seven. Every 5-7 days is preferred, but it is most preferred that anti-progestagen be administered only one time additionally, i.e. in total twice a month. Particularly in the embodiments in which anti-progestagen is administered more than one time additionally, it is preferred to administer it simultaneously with progestagen, i.e. the anti-progestagen does not
- 25 substitute the progestagen but comes in addition. It is important that the anti-progestagen is administered only one day at a row. For HRT regimens it is desired for the anti-progestogen to be dosed in as low an amount as is capable of inhibiting bleeding, without inducing menses.
- 30 In the method of this invention the contraceptive and/or HRT kit consists of four phases, in which the first phase is a single dosage unit comprising an anti-progestogen and optionally a progestogen, the second phase containing progestogen, estrogen or a

mixture thereof, the third phase comprising an anti-progestogen and optionally a progestogen, and the fourth phase containing progestogen, estrogen or a mixture thereof.

- 5 Preferably the dosage of the anti-progestogen in the third and optional further phases is lower than the dosage of the anti-progestogen in the first phase. More preferably the first phase consists of 10 to 150 mg of Org 31710, and most preferably 25 mg of Org 31710, and the third phase (and any optional subsequent phase) consists of 0.5 to 25 mg, more preferably of 2.5 to 12.5 mg, and even more preferably of 5 mg of Org  
10 31710. In the case of a more than four-phase regimen involving more than two times administration of anti-progestagen, the first phase dosage will generally be the same as above, but it is possible to further decrease the dosage in the subsequent phases.

- For HRT regimens dosage units comprising the anti-progestogen units as above and  
15 units comprising an estrogen, progestogen or mixtures thereof are envisaged. Estrogens which can be used include 17 $\beta$ -estradiol and ethinyl estradiol. Mestranol (17- $\alpha$ -ethinyl estradiol 3-methylether) and conjugated estrogens are also useful estrogens. Suitable amounts of ethinyl estradiol per dosage unit are between 0.005 and 0.1 mg. Of course amounts having equivalent activity of other estrogens can also be  
20 used. As an approximation, 1 mg of 17 $\beta$ -estradiol is equivalent in estrogenic activity to 0.015 mg of ethinyl estradiol and 0.030 mg of mestranol.

- The progestogen and anti-progestogen are incorporated into dosage units for oral administration. The term "dosage unit" generally refers to physically discrete units  
25 suitable as unitary dosages for humans, each containing a predetermined quantity of active material calculated to produce the desired effect, for instance tablets, pills, powders, suppositories, capsules and the like.

- Methods and compositions for making such dosage units are well-known to those skilled in the art. For example, conventional techniques for making tablets and pills,  
30 containing active ingredients, are described in the standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture).

For making dosage units, e.g. tablets, the use of conventional additives, e.g. fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used in the one or more of the compositions.

- 5     Suitable carriers with which the compositions can be administered include lactose, starch, cellulose derivatives and the like used in suitable amounts. Lactose is a preferred carrier. Mixtures of carriers can also be used.

- 10     A process of manufacturing the kit of the invention comprises mixing predetermined quantities of progestogen (for instance desogestrel, 3-ketodesogestrel, or mixtures thereof) or anti-progestogen (for instance Org 31710) with predetermined quantities of excipients and converting the mixture into dosage units containing progestogen or anti-progestogen.

- 15     For HRT regimens unit dosages may be obtained by mixing predetermined quantities of progestogen and estrogen.

Preferred kits contain a total of 20 to 32 of said daily sequential dosage units.

Converting the mixture into dosage units generally involves moulding the mixture into a tablet, filling a capsule with a dried mixture, or filling a capsule with a wet mixture.

- 20     A preferred process of manufacturing the pharmaceutical product according to the invention involves incorporating the desired dosages of contraceptive steroid (for example desogestrel, 3-ketodesogestrel, or mixtures thereof) into tablets by techniques such as wet granulation tableting techniques. The package containing the dosage units will contain between 7 and 180, preferably 28, dosage units.

- 25     While the description hereinbefore refers to daily dosage units making up the anticonceptive or HRT kit, the method of treatment according to the invention extends to any other suitable form of administration. Therefore, the invention relates to pharmaceutical preparations capable of releasing progestagen and anti-progestagen, optionally simultaneously, in accordance with the regimen described above. Thus the administration in four or more phases of anti-progestagen and progestagen can be effectuated not only through tablets, but also by means of an implant system, a vaginal ring, injectable systems, transdermal systems, or by any combination thereof.



(particularly: the progestagen administered as a tablet, the anti-progestagen in the form of a non-oral system such as an implant).

The invention is further explained by the following illustrative examples.

5

### Example I

The following coated tablets intended for once daily administration were made:

Composition (per tablet):

10

#### Tablet I

<u>Compound</u>	<u>Amount (mg/tablet)</u>
desogestrel	0.075
corn starch	6.500
15 povidone	1.950
stearic acid	0.650
colloidal silicone dioxide	0.650
dl- $\alpha$ -tocopherol	0.080
lactose	qsad 65.000

20

Coating layer: (filmcoat-dry)

<u>Compound</u>	<u>Amount (mg/tablet)</u>
hydroxypropylmethylcellulose	0.75
25 polyethylene glycol 400	0.15
titanium dioxide	0.1125
talc	0.1875

## Tablet II

	<u>Compound</u>	<u>Amount (mg/tablet)</u>
	Org 31710	25
5	corn starch	6.500
	povidone	1.950
	stearic acid	0.650
	colloidal silicone dioxide	0.650
	dl- $\alpha$ -tocopherol	0.080
10	lactose	qsad 65.000

The same coating layer as for tablet I was used.

## Tablet III

15

	<u>Compound</u>	<u>Amount (mg/tablet)</u>
	Org 31710	5
	corn starch	6.500
	povidone	1.950
20	stearic acid	0.650
	colloidal silicone dioxide	0.650
	dl- $\alpha$ -tocopherol	0.080
	lactose	qsad 65.000

25 The same coating layer as for tablet I was used.

The tablets were packed in push-through packs as follows:

- 1 Tablet II
- 13 Tablets I
- 30 1 Tablet III
- 13 Tablets I

The push through packs are placed in folding cartons, which are additionally sealed in aluminum sachets.

5    Example II

The tablets of Example I, along with similar tablets containing 0.030 and 0.050 mg of desogestrel were tested in healthy female volunteers in a non-public, double-blind randomized study. Ovulation was completely inhibited with the tablets of Example I.

- 10   Furthermore, the use of the tablets of Example I also had a low percentage of bleeding and spotting days in comparison to conventional regimens of desogestrel.

## Claims

1. A contraceptive and/or HRT (hormone replacement therapy) kit comprising sequential daily dosage units each containing as the sole contraceptively effective ingredient a progestogen, or as effective ingredient for HRT a progestogen with or without an estrogen or an estrogen only, and further two dosage units comprising an anti-progestogen.
2. The contraceptive and/or HRT kit of claim 1 wherein said kit contains a total of 20 to 32 dosage units.
3. The contraceptive and/or HRT kit of claim 1 or 2 consisting of four phases, in which the first phase is a single dosage unit containing an anti-progestogen and optionally a progestogen, the second phase containing progestogen, estrogen or a mixture thereof, the third phase containing an anti-progestogen and optionally a progestogen, and the fourth phase containing progestogen, estrogen or a mixture thereof.
4. The contraceptive and/or HRT kit of claim 1 consisting of four phases, in which the first phase is a single dosage unit containing an anti-progestogen and optionally a progestogen, the second phase consists of 9-15 dosage units containing progestogen, estrogen or a mixture thereof, the third phase is a single dosage unit containing an anti-progestogen and optionally a progestogen, and the fourth phase consists of 9-15 dosage units containing progestogen, estrogen or a mixture thereof.
5. A contraceptive and/or HRT kit 1 consisting of four to eight phases in which the odd-numbered phases all comprise a single dosage unit containing an anti-progestogen and optionally a progestogen and the even-numbered phases all consist of 8-15 dosage units containing progestogen, estrogen or a mixture thereof.

6. The contraceptive and/or HRT kit of claim 3, 4 or 5, further comprising placebo dosage units.
7. The contraceptive and/or HRT kit of any one of claims 3 to 6, wherein the dosage of the anti-progestogen in the third phase and, if present, subsequent phases, is lower than the dosage of the anti-progestogen in the first phase.
8. The contraceptive and/or HRT kit of any one of claims 1-7, wherein the progestogen is desogestrel present in a quantity of 75 µg per dosage unit and the antiprogestogen is Org 31710 present in a quantity of 25 mg in the first phase and in a quantity of 2.5 to 12.5 mg in the third and subsequent phases.
9. The use of daily dosage units consisting essentially a progestogen, and of an anti-progestogen, in the preparation of a drug delivery system, said drug delivery system characterized by consisting of daily dosage units containing only a progestogenic compound as therapeutically effective ingredient and two to seven dosage units comprising anti-progestogen, one of which is administered at the beginning, and the other or others divided regularly throughout the cycle.
10. The use of oral daily dosage units consisting essentially of an estrogen and a progestogen, and of an anti-progestogen, in the preparation of a drug delivery system, said drug delivery system characterized by consisting of daily dosage units containing progestogen and/or estrogen as therapeutically effective ingredient and two to seven dosage units comprising an anti-progestogen, one of which is administered at the beginning and the other or others divided regularly throughout the cycle.

11. A process of manufacturing a drug delivery system according to any one of claims 1-7 comprising mixing predetermined quantities of a progestogen, and if required estrogen, with predetermined quantities of excipients and converting the mixture into dosage units each comprising the progestogen and optionally the estrogen or the mixture of the progestogen and the estrogen, and mixing predetermined quantities of an anti-progestogen with predetermined quantities of excipients and optionally predetermined quantities of a progestogen and converting the mixture into dosage units each comprising the anti-progestogen, and packaging a plurality of said dosage units into a kit.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 97/03288

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/58 A61K31/57 A61K31/565

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 21927 A (MEDICAL COLLEGE OF HAMPTON ROA ;HODGEN GARY D (US)) 11 November 1993 cited in the application see claims ---	1-12
A	WO 96 15794 A (BALANCE PHARMACEUTICALS INC) 30 May 1996 see claim 1 ---	1-11
A	KEKKONEN R ET AL: "INTERFERENCE WITH OVULATION BY SEQUENTIAL TREATMENT WITH THE ANTIPROGESTERONE RU486 AND SYNTHETIC PROGESTIN" FERTILITY AND STERILITY, vol. 53, no. 4, pages 747-750, XP000569448 see page 749, column 2, paragraph 7 - page 750, column 2 --- -/--	1-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 October 1997

Date of mailing of the international search report

28.10.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Telex 31 651 epo nl.

Authorized officer

# INTERNATIONAL SEARCH REPORT

Int .tional Application No

PCT/EP 97/03288

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 04156 A (AKZO NV ;BERGINK ENGELBERT WILLEM (NL)) 3 March 1994 see abstract	1-12
A	--- KEKKONEN R ET AL: "SEQUENTIAL REGIMEN OF THE ANTIPROGESTERONE RU486 AND SYNTHETIC PROGESTIN FOR CONTRACEPTION" FERTILITY AND STERILITY, vol. 60, no. 4, pages 610-615, XP000569447 see abstract	1-12
A	--- DE 43 44 463 A (SCHERING AG) 29 June 1995 see claims -----	1-12



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int :ional Application No

PCT/EP 97/03288

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9321927 A	11-11-93	WO 9321926 A	11-11-93
		AU 1918092 A	29-11-93
		AU 4368593 A	29-11-93
		CA 2131911 A	11-11-93
		CN 1079651 A	22-12-93
		EP 0646008 A	05-04-95
		FI 945207 A	04-11-94
		JP 8509456 T	08-10-96
		NO 944210 A	04-11-94
		NZ 253405 A	24-06-97
		US 5622943 A	22-04-97
		ZA 9303153 A	06-12-93
-----			
WO 9615794 A	30-05-96	EP 0792152 A	03-09-97
-----			
WO 9404156 A	03-03-94	AU 4708993 A	15-03-94
		MX 9304931 A	31-08-94
		ZA 9305617 A	07-03-94
-----			
DE 4344463 A	29-06-95	WO 9517193 A	29-06-95
		EP 0735882 A	09-10-96
-----			